What assessments are important to monitor during antipsychotic therapy?

• A. Mental status, symptom severity, EPS scales (AIMS), metabolic parameters (glucose, lipids, weight), CBC for clozapine, vital signs, and adherence.
• B. Only blood pressure and heart rate.
• C. Only cognitive testing.
• D. No structured assessments are required.

Answer: (A)

Regular, comprehensive monitoring during antipsychotic therapy is essential to balance effectiveness with safety. Tracking mental status and symptom severity shows whether the treatment is helping and if the dose needs adjustment. Because antipsychotics can cause movement disorders, using standardized EPS scales (like AIMS) helps detect and manage these side effects early. All antipsychotics carry a risk of metabolic effects—weight gain, glucose intolerance, and dyslipidemia—so routinely checking metabolic parameters (weight, fasting glucose or HbA1c, lipids) is important to prevent long-term harm. For clozapine, regular complete blood counts are mandatory due to the risk of agranulocytosis. Vital signs are needed to catch cardiovascular effects and overall safety, and assessing adherence is key to ensuring the medication is taken as prescribed and to prevent relapse. Taken together, these assessments provide a complete picture of both how well the therapy is working and what safety concerns may arise. Focusing on only one domain, like just blood pressure or just cognitive testing, misses the broader safety and efficacy picture, and no structured assessments would leave important monitoring gaps.